Association of Diabetes and Severe COVID-19 Outcomes: A Rapid Review and Meta-Analysis

Kubjane, Mmamapudi; McCreedy, Nicole; Cariou, Bertrand; Rubio, Miguel A.; Panton, Ulrik Haagen; Hvid, Christian; Hettiarachchige, Nadilka; Mearns, Helen

doi:10.2139/ssrn.3670683

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most COVID-19 patients with comorbidities identified in this study were COVID-19 patients with a comorbid history of Hypertension (33.3%) and Diabetes mellitus (27.3%). It is known from previous studies that COVID-19 patients with comorbidities have a higher mortality rate than patients without comorbidities (18). This is supported by research which shows that 88% of deaths in SARS-CoV-2 positive patients are caused by a history of comorbidities (19).…”

Section: Characteristicsmentioning

confidence: 87%

Comorbidities Effects in COVID-19 Patients on Laboratory Inflammation Markers Test Results

Apriani¹,

Rachmad²,

Hidayah³

et al. 2022

Jour. Health Sci Prev

View full text Add to dashboard Cite

Inflammatory reactions play an important role in the pathophysiology of COVID-19. Levels of D-dimer, procalcitonin (PCT) and C-reactive Protein (CRP) are known to increase in response to an inflammatory reaction. Comorbid COVID-19 patients are often associated with severe conditions and do not survive. In handling COVID-19 patients with comorbidities, it is necessary to recommend specific laboratory examinations to make the actions given more effective and efficient and reduce costs and treatment time. This study aims to determine the effect of comorbid on the results of laboratory examination of inflammatory markers. The study was conducted in June – August 2022 at Siloam Lippo Village Hospital. Subjects and laboratory results were presented descriptively. Test the effect of comorbid and inflammatory marker parameters using a statistical regression test (a=0.5%). Statistical tests showed no significant effect on comorbidity on laboratory results of inflammatory markers D-dimer (P= 0.467) and PCT (P= 0.834). Comorbidities significantly affected CRP examination results (P = 0.002). In this case, it is necessary to prioritize all comorbid COVID-19 patients to have an early CRP examination to treat rapidly decreasing oxygen saturation, deep vein thrombosis and pulmonary embolism and death.

show abstract

Section: Characteristicsmentioning

confidence: 87%